Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
EBIATMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Cyclerion Therapeutics (CYCN) EBIAT (2019 - 2025)

Cyclerion Therapeutics (CYCN) has disclosed EBIAT for 7 consecutive years, with -$976000.0 as the latest value for Q3 2025.

  • For Q3 2025, EBIAT fell 34.99% year-over-year to -$976000.0; the TTM value through Sep 2025 reached -$2.2 million, up 59.14%, while the annual FY2024 figure was -$3.1 million, 41.92% up from the prior year.
  • EBIAT hit -$976000.0 in Q3 2025 for Cyclerion Therapeutics, down from -$324000.0 in the prior quarter.
  • Across five years, EBIAT topped out at $44.1 million in Q4 2022 and bottomed at -$16.2 million in Q2 2021.
  • Average EBIAT over 5 years is -$3.0 million, with a median of -$4.2 million recorded in 2023.
  • Year-over-year, EBIAT soared 509.28% in 2022 and then plummeted 104.07% in 2023.
  • Cyclerion Therapeutics' EBIAT stood at -$10.8 million in 2021, then skyrocketed by 509.28% to $44.1 million in 2022, then tumbled by 104.07% to -$1.8 million in 2023, then skyrocketed by 129.53% to $530000.0 in 2024, then tumbled by 284.15% to -$976000.0 in 2025.
  • According to Business Quant data, EBIAT over the past three periods came in at -$976000.0, -$324000.0, and -$1.4 million for Q3 2025, Q2 2025, and Q1 2025 respectively.